NA therapy

DRUG3 trials

Sponsors

GlaxoSmithKline, Ausper Biopharma Co., Ltd.

Conditions

Chronic Hepatitis BHepatitis B

Phase 2

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

CompletedNCT04676724

GlaxoSmithKlineHepatitis B

Start: 2021-01-28End: 2023-02-17Updated: 2024-05-02

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

RecruitingNCT07137910

Ausper Biopharma Co., Ltd.Chronic Hepatitis B

Start: 2025-09-04End: 2027-06-01Target: 200Updated: 2026-08-05

Phase 3

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Active, not recruitingNCT07246889

Ausper Biopharma Co., Ltd.Chronic Hepatitis B

Start: 2025-08-12End: 2027-10-31Updated: 2026-05-04

Related Papers

Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study).

2025-10-032 citations

Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.

2024-08-2923 citations